Rising Pharma Holding, Inc. FDA Inspection Record
Rising Pharma Holding, Inc. is an FDA-inspected facility (FEI 3015784623) located in East Brunswick, NJ, US. RegDataLab tracks 1 FDA inspection at this facility.
What FDA found at this site
- Latest inspection
- Nov 3, 2023: No Action Indicated (NAI)
- Inspections on record
- 1 (1 NAI)
- Last OAI inspection
- None on record
- Warning letters
- None matched to this FEI. Many letters do not state an FEI: search warning letters by company name
- Recalls as the recalling firm
- 12, latest Jul 13, 2026
- Import refusals
- 2
Inspections and what FDA cited
| Date | Result | What FDA cited |
|---|---|---|
| Nov 3, 2023 | No Action Indicated (NAI) | No citations listed |
Recalls
| Date | Class | Recall | Product and reason |
|---|---|---|---|
| Jul 13, 2026 | Class II | D-0724-2026 | Rising, Cyproheptadine Hydrochloride Syrup, 2mg/5 mL, 473 mL (ONE PINT), Rx only… Presence of Precipitate: medication was crystallizing and particles floating in the bottle |
| Mar 3, 2026 | Class II | D-0384-2026 | Product label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only… Failed Impurities/Degradation Specifications: An out-of-specification result observed during 9th-month long term stability testing |
| Oct 7, 2025 | Class II | D-0029-2026 | Carbidopa, Levodopa, Entacapone Tablets, 25 mg/100 mg/200 mg, 100-count bottle, Rx Only… Product mix up: complaint received that sealed medication bottle contained Carbidopa, Levodopa, and Entacapone film-coated tablets (37.5… |
| Mar 5, 2025 | Class II | D-0277-2025 | Duloxetine Delayed-Release Capsules, USP, 30 mg, 1,000-count bottle, Rx only, Distributed… CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit. |
| Dec 30, 2024 | Class II | D-0188-2025 | Duloxetine Delayed-Release Capsules USP 30 mg, a) 30 count (NDC 57237-018-30) and b) 1000… and 2 more products CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit. |
| Nov 19, 2024 | Class II | D-0105-2025 | Duloxetine Delayed-Release Capsules USP, 20 mg, 60 count bottles, Rx only, Distributed by… and 2 more products CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit |
| Jun 24, 2024 | Class III | D-0599-2024 | Diflorasone Diacetate Ointment, USP, 0.05%, 60g tube, Rx only, Mfd. By: Lyne Laboratories… Failed Impurities/Degradation Specifications: The impurity results at 12 months stability testing,did not conform to the specification… |
| May 16, 2024 | Class III | D-0541-2024 | Pregabalin Capsules 50mg, 1000-count bottle, Rx Only, Manufactured for: Rising Pharma… Presence of Foreign Tablets/Capsules: Complaint received from a re-packager, American Health Packaging (AHP), where a foreign tablet was… |
| Dec 29, 2023 | Class II | D-0222-2024 | buPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150mg, 30-count bottles, Rx… Presence of Foreign Tablets/Capsules |
| Feb 15, 2023 | Class II | D-0348-2023 | Warfarin Sodium Tablets, USP 1 mg, 100-count bottle, Rx Only, Distributed by: Rising… Failed Impurities/Degradation Specifications |
FDA record score
32 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.
10 records behind this number
| Record | Date | Points x age weight | Adds |
|---|---|---|---|
| Class II recall D-0724-2026, this FEI as the recalling firm | Jul 13, 2026 | 4 x 1 | 4 |
| Class II recall D-0384-2026, this FEI as the recalling firm | Mar 3, 2026 | 4 x 1 | 4 |
| Class II recall D-0029-2026, this FEI as the recalling firm | Oct 7, 2025 | 4 x 1 | 4 |
| Class II recall D-0277-2025, this FEI as the recalling firm | Mar 5, 2025 | 4 x 1 | 4 |
| Class II recall D-0188-2025, this FEI as the recalling firm | Dec 30, 2024 | 4 x 1 | 4 |
| Class II recall D-0105-2025, this FEI as the recalling firm | Nov 19, 2024 | 4 x 1 | 4 |
| Class II recall D-0222-2024, this FEI as the recalling firm | Dec 29, 2023 | 4 x 0.6 | 2.4 |
| Class II recall D-0348-2023, this FEI as the recalling firm | Feb 15, 2023 | 4 x 0.6 | 2.4 |
| Class II recall D-0573-2022, this FEI as the recalling firm | Feb 7, 2022 | 4 x 0.6 | 2.4 |
| Class II recall D-0005-2022, this FEI as the recalling firm | Sep 2, 2021 | 4 x 0.25 | 1 |
When each source was last refreshed
| Records | Last refreshed | Source as of | Status |
|---|---|---|---|
| Inspections | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Inspection citations | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Compliance actions (warning letters, injunctions and other action types) | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
| Warning letter text | Nov 16, 2026 | Newest record Nov 10, 2026 | Current |
| Recalls (Enforcement Report) | Nov 16, 2026 | Newest record Nov 11, 2026 | Current |
| Form 483s and inspection documents | Nov 13, 2026 | Newest record Nov 12, 2026 | Current |
| Import refusals | Nov 15, 2026 | Newest record Nov 5, 2026 | Current |
Reviewing Rising Pharma Holding, Inc. as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Rising Pharma Holding, Inc. yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Facility details
- Company
- Rising Pharma Holding, Inc.
- Location
- East Brunswick, NJ (US)
- Source
- inspections